sub:assertion {
d:DB00472 dv:ddi-interactor-in dr:DB00472_DB01142 .
d:DB01142 dv:ddi-interactor-in dr:DB00472_DB01142 .
dr:DB00472_DB01142 dcterms:identifier "drugbank_resource:DB00472_DB01142" ;
dcterms:title "DDI between Fluoxetine and Doxepin - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Fluoxetine and Doxepin - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB01142]"@en .
}